Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis

References

• Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–126.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
   PubMed Web of Science ®Google Scholar
• Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–241.
   PubMed Web of Science ®Google Scholar
• Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol. 2012;74:13–40.
   PubMed Web of Science ®Google Scholar
• Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341–355.
   PubMed Web of Science ®Google Scholar
• Bentzon JF, Otsuka F, Virmani R, et al. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852–1866.
   PubMed Web of Science ®Google Scholar
• Kockx MM, Gry DM, Muhring J, et al. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation. 1998;97(23):2307–2315.
   PubMed Web of Science ®Google Scholar
• Schrijvers DM, Gry DM, Kockx MM, et al. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25(6):1256–1261.
   PubMed Web of Science ®Google Scholar
• Crisby M, Kallin B, Thyberg J, et al. Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis. 1997;130(1):17–27.
   PubMed Web of Science ®Google Scholar
• Martinet W, Schrijvers DM, De Meyer GRY. Necrotic cell death in atherosclerosis. Basic Res Cardiol. 2011;106(5):749–760.
   PubMed Web of Science ®Google Scholar
• Tangirala RK, Jerome WG, Jones NL, et al. Formation of cholesterol monohydrate crystals in macrophage-derived foam cells. J Lipid Res. 1994;35(1):93–104.
   PubMed Web of Science ®Google Scholar
• Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev. 2006;20(1):1–15.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tabas I. Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association? J Atheroscler Thromb. 2014;21(5):381–390.
   PubMed Web of Science ®Google Scholar
• Waring P. Redox active calcium ion channels and cell death. Arch Biochem Biophys. 2005;434(1):33–42.
   PubMed Web of Science ®Google Scholar
• Martinet W, Knaapen MWM, Gry DM, et al. Elevated levels of oxidative DNA damage and dna repair enzymes in human atherosclerotic plaques. Circulation. 2002;106(8):927–932.
   PubMed Web of Science ®Google Scholar
• Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal. Genes Dev. 2005;19(17):1951–1967.
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Lemasters JJ. Glycine blocks opening of a death channel in cultured hepatic sinusoidal endothelial cells during chemical hypoxia. Cell Death Differ. 2001;8(8):850–858.
   PubMed Web of Science ®Google Scholar
• Oumouna-Benachour K, Hans CP, Suzuki Y, et al. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death. Circulation. 2007;115(18):2442–2450.
   PubMed Web of Science ®Google Scholar
• Hans CP, Feng Y, Naura AS, et al. Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE(−/−) mice: effects on eNOS and oxidative stress. PLoS One. 2009;4(10):e7430.
   PubMed Web of Science ®Google Scholar
• Bano D, Young KW, Guerin CJ, et al. Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell. 2005;120(2):275–285.
   PubMed Web of Science ®Google Scholar
• Bruce JIE Metabolic regulation of the PMCA: role in cell death and survival. Cell Calcium 2017. Published online 2017 Jun 8.
   PubMed Web of Science ®Google Scholar
• Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta. 2006;1757(9–10):1371–1387.
   PubMed Web of Science ®Google Scholar
• Brouckaert G, Kalai M, Krysko DV, et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell. 2004;15(3):1089–1100.
   PubMed Web of Science ®Google Scholar
• Thorp E, Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol. 2009;86(5):1089–1095.
   PubMed Web of Science ®Google Scholar
• Kojima Y, Weissman IL, Leeper NJ. The role of efferocytosis in atherosclerosis. Circulation. 2017;135(5):476–489.
   PubMed Web of Science ®Google Scholar
• Kojima Y, Volkmer JP, McKenna K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536(7614):86–90.
   PubMed Web of Science ®Google Scholar
• Cai B, Thorp EB, Doran AC, et al. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc Natl Acad Sci U S A. 2016;113(23):6526–6531.
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Kinugawa K, Zoll J, et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation. 2007;115(16):2168–2177.
   PubMed Web of Science ®Google Scholar
• Ogden CA, deCathelineau A, Hoffmann PR, et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med. 2001;194(6):781–795.
   PubMed Web of Science ®Google Scholar
• Sambrano GR, Terpstra V, Steinberg D. Independent mechanisms for macrophage binding and macrophage phagocytosis of damaged erythrocytes. Arterioscler Thromb Vasc Biol. 1997;17(12):3442–3448.
   PubMed Web of Science ®Google Scholar
• Shaw PX, Horkko S, Tsimikas S, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol. 2001;21(8):1333–1339.
   PubMed Web of Science ®Google Scholar
• de Souza AW, Westra J, Limburg PC, et al. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev. 2012;11(12):909–917.
   PubMed Web of Science ®Google Scholar
• Kalinina N, Agrotis A, Antropova Y, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol. 2004;24(12):2320–2325.
   PubMed Web of Science ®Google Scholar
• Kanellakis P, Agrotis A, Kyaw TS, et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31(2):313–319.
   PubMed Web of Science ®Google Scholar
• Inoue K, Kawahara K, Biswas KK, et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol. 2007;16(3):136–143.
   PubMed Web of Science ®Google Scholar
• Porto A, Palumbo R, Pieroni M, et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J. 2006;20(14):2565–2566.
   PubMed Web of Science ®Google Scholar
• Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101(7):2652–2660.
   PubMed Web of Science ®Google Scholar
• Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(8):C13–C18.
   PubMed Web of Science ®Google Scholar
• Lundberg B. Chemical composition and physical state of lipid deposits in atherosclerosis. Atherosclerosis. 1985;56(1):93–110.
   PubMed Web of Science ®Google Scholar
• Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med. 2014;276(6):618–632.
   PubMed Web of Science ®Google Scholar
• Cherubini A, Vigna GB, Zuliani G, et al. Role of antioxidants in atherosclerosis: epidemiological and clinical update. Curr Pharm Des. 2005;11(16):2017–2032.
   PubMed Web of Science ®Google Scholar
• Otani H. Site-specific antioxidative therapy for prevention of atherosclerosis and cardiovascular disease. Oxid Med Cell Longev. 2013;2013:796891.
   PubMedGoogle Scholar
• Grootaert MO, Schrijvers DM, Van Spaendonk H, et al. NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice. Atherosclerosis. 2016;252:166–174.
   PubMed Web of Science ®Google Scholar
• Park J, Park E, Ahn BH, et al. NecroX-7 prevents oxidative stress-induced cardiomyopathy by inhibition of NADPH oxidase activity in rats. Toxicol Appl Pharmacol. 2012;263(1):1–6.
   PubMed Web of Science ®Google Scholar
• Thu VT, Kim HK. Long le T, et al. RNecroX-5 Prevents Hypoxia/Reoxygenation Injury by Inhibiting Mitochondrial Calcium Uniporter. Cardiovasc Res. 2012;94(2):342–350.
   PubMed Web of Science ®Google Scholar
• Kockx M, Jessup W, Cyclosporin KL. A and atherosclerosis–cellular pathways in atherogenesis. Pharmacol Ther. 2010;128(1):106–118.
   PubMed Web of Science ®Google Scholar
• Maderna P, Godson C. Phagocytosis of apoptotic cells and the resolution of inflammation. Biochim Biophys Acta. 2003;1639(3):141–151.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. 2006;176(12):7657–7665.
   PubMed Web of Science ®Google Scholar
• Forouzandeh F, Salazar G, Patrushev N, et al. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014;3(6):e001202.
   PubMed Web of Science ®Google Scholar
• Bae H-B, Zmijewski JW, Deshane JS, et al. AMP-activated protein kinase enhances the phagocytic ability of macrophages and neutrophils. FASEB J. 2011;25(12):4358–4368.
   PubMed Web of Science ®Google Scholar
• Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1(6):489–495.
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Galluzzi L, Vanden Berghe T, et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11(10):700–714.
   PubMed Web of Science ®Google Scholar
• Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4(5):313–321.
   PubMed Web of Science ®Google Scholar
• Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112–119.
   PubMed Web of Science ®Google Scholar
• Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, et al. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 2014;15(2):135–147.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Vandenabeele P, et al. Classification of cell death: recommendations of the nomenclature committee on cell death2009. Cell Death Differ. 2009;16(1):3–11
   PubMed Web of Science ®Google Scholar
• He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell. 2009;137(6):1100–1111.
   PubMed Web of Science ®Google Scholar
• Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell. 2009;138(2):229–232.
   PubMed Web of Science ®Google Scholar
• Conrad M, Angeli JP, Vandenabeele P, et al. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2016;15(5):348–366.
   PubMed Web of Science ®Google Scholar
• Dondelinger Y, Darding M, Bertrand MJ, et al. Poly-ubiquitination in TNFR1-mediated necroptosis. Cell Mol Life Sci. 2016;73(11–12):2165–2176.
   PubMed Web of Science ®Google Scholar
• Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133(4):693–703.
   PubMed Web of Science ®Google Scholar
• Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15(6):362–374.
   PubMed Web of Science ®Google Scholar
• Vanlangenakker N, Vanden Berghe T, Bogaert P, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2011;18(4):656–665.
   PubMed Web of Science ®Google Scholar
• Vanlangenakker N, Bertrand MJ, Bogaert P, et al. TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members. Cell Death Dis. 2011;2:e230.
   PubMed Web of Science ®Google Scholar
• Vercammen D, Beyaert R, Denecker G, et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med. 1998;187(9):1477–1485.
   PubMed Web of Science ®Google Scholar
• Zheng L, Bidere N, Staudt D, et al. Competitive control of independent programs of tumor necrosis factor receptor-induced cell death by TRADD and RIP1. Mol Cell Biol. 2006;26(9):3505–3513.
   PubMed Web of Science ®Google Scholar
• Oberst A, Dillon CP, Weinlich R, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature. 2011;471(7338):363–367.
   PubMed Web of Science ®Google Scholar
• O’Donnell MA, Perez-Jimenez E, Oberst A, et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol. 2011;13(12):1437–1442.
   PubMed Web of Science ®Google Scholar
• Kaiser WJ, Upton JW, Long AB, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471(7338):368–372.
   PubMed Web of Science ®Google Scholar
• Wu J, Huang Z, Ren J, et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res. 2013;23(8):994–1006.
   PubMed Web of Science ®Google Scholar
• Hildebrand JM, Tanzer MC, Lucet IS, et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad Sci U S A. 2014;111(42):15072–15077.
   PubMed Web of Science ®Google Scholar
• Wang H, Sun L, Su L, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell. 2014;54(1):133–146.
   PubMed Web of Science ®Google Scholar
• Dondelinger Y, Declercq W, Montessuit S, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 2014;7(4):971–981.
   PubMed Web of Science ®Google Scholar
• Cai Z, Jitkaew S, Zhao J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol. 2014;16(1):55–65.
   PubMed Web of Science ®Google Scholar
• Karunakaran D, Geoffrion M, Wei L, et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv. 2016;2(7):e1600224.
   PubMed Web of Science ®Google Scholar
• Lin J, Li H, Yang M, et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep. 2013;3(1):200–210.
   PubMed Web of Science ®Google Scholar
• Xie T, Peng W, Liu Y, et al. Structural basis of RIP1 inhibition by necrostatins. Structure. 2013;21(3):493–499.
   PubMed Web of Science ®Google Scholar
• Dondelinger Y, Aguileta MA, Goossens V, et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ. 2013;20(10):1381–1392.
   PubMed Web of Science ®Google Scholar
• Legarda-Addison D, Hase H, Ma O, et al. NEMO/IKKgamma regulates an early NF-kappaB-independent cell-death checkpoint during TNF signaling. Cell Death Differ. 2009;16(9):1279–1288.
   PubMed Web of Science ®Google Scholar
• Harris PA, Bandyopadhyay D, Berger SB, et al. Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis. ACS Med Chem Lett. 2013;4(12):1238–1243.
   PubMed Web of Science ®Google Scholar
• Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol. 2013;14(11):727–736.
   PubMed Web of Science ®Google Scholar
• Graham IM, Catapano AL, Wong ND. Current guidelines on prevention with a focus on dyslipidemias. Cardiovasc Diagn Ther. 2017;7(Suppl 1):S4–S10.
   PubMedGoogle Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Sahebkar A, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229.
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bacchetti T, Banach M, et al. Impact of Statin therapy on plasma MMP-3, MMP-9, and TIMP-1 concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Angiology. 2017;68(10):850–862.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Kotani K, Serban C, et al. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015;241(2):433–442.
   PubMed Web of Science ®Google Scholar
• Serban C, Sahebkar A, Ursoniu S, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep. 2015;5:9902.
   PubMed Web of Science ®Google Scholar
• Uk S, Fazio S, Mf L. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14(1):1–10.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682–689.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(2):199–207.e15.
   PubMed Web of Science ®Google Scholar
• Meng L, Jin W, Wang X. RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality. Proc Natl Acad Sci U S A. 2015;112(35):11007–11012.
   PubMed Web of Science ®Google Scholar
• Pa H, Bw K, Bandyopadhyay D, et al. DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors. J Med Chem. 2016;59(5):2163–2178.
   PubMed Web of Science ®Google Scholar
• Harris PA, Berger SB, Jeong JU, et al. Discovery of a first-in-class Receptor Interacting Protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. J Med Chem. 2017;60(4):1247–1261.
   PubMed Web of Science ®Google Scholar
• Ren Y, Su Y, Sun L, et al. Discovery of a highly potent, selective, and metabolically stable inhibitor of Receptor-Interacting Protein 1 (RIP1) for the treatment of systemic inflammatory response syndrome. J Med Chem. 2017;60(3):972–986.
   PubMed Web of Science ®Google Scholar
• Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1046–1051.
   PubMed Web of Science ®Google Scholar
• Rojas-Rivera D, Delvaeye T, Roelandt R, et al. When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157. Cell Death Differ. 2017;24(6):1100–1110.
   PubMed Web of Science ®Google Scholar
• Hofmans S, Devisscher L, Martens S, et al. Tozasertib analogues as inhibitors of necroptotic cell death. J Med Chem. 2018;61(5):1895–1920.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Vereecke L, Bertrand MJ, et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature. 2014;513(7516):95–99.
   PubMed Web of Science ®Google Scholar
• Kearney CJ, Cullen SP, Clancy D, et al. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis. Febs J. 2014;281(21):4921–4934.
   PubMed Web of Science ®Google Scholar
• Kaiser WJ, Sridharan H, Huang C, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem. 2013;288(43):31268–31279.
   PubMed Web of Science ®Google Scholar
• Mandal P, Berger SB, Pillay S, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014;56(4):481–495.
   PubMed Web of Science ®Google Scholar
• Newton K, Dugger DL, Wickliffe KE, et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science. 2014;343(6177):1357–1360.
   PubMed Web of Science ®Google Scholar
• Rodriguez DA, Weinlich R, Brown S, et al. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ. 2016;23(1):76–88.
   PubMed Web of Science ®Google Scholar
• Li JX, Feng JM, Wang Y, et al. The B-raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis. 2014;5:e1278.
   PubMed Web of Science ®Google Scholar
• Martens S, Jeong M, Tonnus W, et al. Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Cell Death Dis. 2017;8(6):e2904.
   PubMedGoogle Scholar
• Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1–2):213–227.
   PubMed Web of Science ®Google Scholar
• Geserick P, Hupe M, Moulin M, et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol. 2009;187(7):1037–1054.
   PubMed Web of Science ®Google Scholar
• Kelliher MA, Grimm S, Ishida Y, et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 1998;8(3):297–303.
   PubMed Web of Science ®Google Scholar